Bruce E Miller1, Ruth J Mayer1, Navin Goyal2, Joanne Bal3, Nigel Dallow4, Malcolm Boyce5, Donald Carpenter1, Alison Churchill5, Teresa Heslop6, Aili L Lazaar1. 1. Respiratory Therapy Area Unit, GSK R&D, King of Prussia, Pennsylvania, USA. 2. Clinical Pharmacology Modeling and Simulation, GSK R&D, King of Prussia, Pennsylvania, USA. 3. Clinical Pharmacology Sciences and Study Operations, GSK R&D, Stockley Park, UK. 4. Clinical Statistics, GSK R&D, Stockley Park, UK. 5. Hammersmith Medicines Research, Cumberland Avenue, London, UK. 6. Department of In vitro/In vivo Translation, GlaxoSmithKline, Ware, UK.
Abstract
AIMS: Cathepsin C (CTSC) is necessary for the activation of several serine proteases including neutrophil elastase (NE), cathepsin G and proteinase 3. GSK2793660 is an oral, irreversible inhibitor of CTSC that is hypothesized to provide an alternative route to achieve NE inhibition and was tested in a Phase I study. METHODS: Single escalating oral doses of GSK2793660 from 0.5 to 20 mg or placebo were administered in a randomized crossover design to healthy male subjects; a separate cohort received once daily doses of 12 mg or placebo for 21 days. Data were collected on safety, pharmacokinetics, CTSC enzyme inhibition and blood biomarkers. RESULTS: Single, oral doses of GSK2793660 were able to dose-dependently inhibit whole blood CTSC activity. Once daily dosing of 12 mg GSK2793660 for 21 days achieved ≥90% inhibition (95% CI: 56, 130) of CTSC within 3 h on day 1. Only modest reductions of whole blood enzyme activity of approximately 20% were observed for NE, cathepsin G and proteinase 3. Seven of 10 subjects receiving repeat doses of GSK2793660 manifested epidermal desquamation on palmar and plantar surfaces beginning 7-10 days after dosing commencement. There were no other clinically important safety findings. CONCLUSIONS: GSK2793660 inhibited CTSC activity but not the activity of downstream neutrophil serine proteases. The palmar-plantar epidermal desquamation suggests a previously unidentified role for CTSC or one of its target proteins in the maintenance and integrity of the epidermis at these sites, with some similarities to the phenotype of CTSC-deficient humans.
RCT Entities:
AIMS: Cathepsin C (CTSC) is necessary for the activation of several serine proteases including neutrophil elastase (NE), cathepsin G and proteinase 3. GSK2793660 is an oral, irreversible inhibitor of CTSC that is hypothesized to provide an alternative route to achieve NE inhibition and was tested in a Phase I study. METHODS: Single escalating oral doses of GSK2793660 from 0.5 to 20 mg or placebo were administered in a randomized crossover design to healthy male subjects; a separate cohort received once daily doses of 12 mg or placebo for 21 days. Data were collected on safety, pharmacokinetics, CTSC enzyme inhibition and blood biomarkers. RESULTS: Single, oral doses of GSK2793660 were able to dose-dependently inhibit whole blood CTSC activity. Once daily dosing of 12 mg GSK2793660 for 21 days achieved ≥90% inhibition (95% CI: 56, 130) of CTSC within 3 h on day 1. Only modest reductions of whole blood enzyme activity of approximately 20% were observed for NE, cathepsin G and proteinase 3. Seven of 10 subjects receiving repeat doses of GSK2793660 manifested epidermal desquamation on palmar and plantar surfaces beginning 7-10 days after dosing commencement. There were no other clinically important safety findings. CONCLUSIONS:GSK2793660 inhibited CTSC activity but not the activity of downstream neutrophil serine proteases. The palmar-plantar epidermal desquamation suggests a previously unidentified role for CTSC or one of its target proteins in the maintenance and integrity of the epidermis at these sites, with some similarities to the phenotype of CTSC-deficient humans.
Authors: Christine T N Pham; Jennifer L Ivanovich; Sofia Z Raptis; Barbara Zehnbauer; Timothy J Ley Journal: J Immunol Date: 2004-12-15 Impact factor: 5.422
Authors: Chelsee Hewitt; Derek McCormick; Gerry Linden; Dusan Turk; Igor Stern; Ian Wallace; Louise Southern; Liqun Zhang; Rebecca Howard; Pedro Bullon; Melanie Wong; Richard Widmer; Khaled Abdul Gaffar; Lama Awawdeh; Jim Briggs; Reza Yaghmai; Ethlin W Jabs; Peter Hoeger; Oliver Bleck; Stefan G Rüdiger; Gregor Petersilka; Maurizio Battino; Peter Brett; Faiez Hattab; Mohamed Al-Hamed; Philip Sloan; Carmel Toomes; Mike Dixon; Jacqueline James; Andrew P Read; Nalin Thakker Journal: Hum Mutat Date: 2004-03 Impact factor: 4.878
Authors: Susanne F de Haar; D C Jansen; Ton Schoenmaker; Hilde De Vree; Vincent Everts; Wouter Beertsen Journal: Hum Mutat Date: 2004-05 Impact factor: 4.878
Authors: Bala C Chenna; Linfeng Li; Drake M Mellott; Xiang Zhai; Jair L Siqueira-Neto; Claudia Calvet Alvarez; Jean A Bernatchez; Emily Desormeaux; Elizabeth Alvarez Hernandez; Jana Gomez; James H McKerrow; Jorge Cruz-Reyes; Thomas D Meek Journal: J Med Chem Date: 2020-03-17 Impact factor: 7.446
Authors: Laura E de Vries; Mateo I Sanchez; Katarzyna Groborz; Laurie Kuppens; Marcin Poreba; Christine Lehmann; Neysa Nevins; Chrislaine Withers-Martinez; David J Hirst; Fang Yuan; Shirin Arastu-Kapur; Martin Horn; Michael Mares; Matthew Bogyo; Marcin Drag; Edgar Deu Journal: FEBS J Date: 2019-06-24 Impact factor: 5.542
Authors: Mateo I Sanchez; Laura E de Vries; Christine Lehmann; Jeong T Lee; Kenny K Ang; Christopher Wilson; Steven Chen; Michelle R Arkin; Matthew Bogyo; Edgar Deu Journal: PLoS One Date: 2019-12-18 Impact factor: 3.240
Authors: Michele S Y Tan; Dara Davison; Mateo I Sanchez; Bethany M Anderson; Stephen Howell; Ambrosius Snijders; Laura E Edgington-Mitchell; Edgar Deu Journal: PLoS One Date: 2020-01-10 Impact factor: 3.240
Authors: Martina Oriano; Francesco Amati; Andrea Gramegna; Anthony De Soyza; Marco Mantero; Oriol Sibila; Sanjay H Chotirmall; Antonio Voza; Paola Marchisio; Francesco Blasi; Stefano Aliberti Journal: Int J Mol Sci Date: 2021-06-01 Impact factor: 5.923